Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.

ABSTRACT:

Aims

Metformin is the most widely used oral anti-diabetes agent and has considerable benefits over other therapies, yet 20-30% of people develop gastrointestinal side effects, and 5% are unable to tolerate metformin due to the severity of these side effects. The mechanism for gastrointestinal side effects and their considerable inter-individual variability is unclear. We have recently shown the association between organic cation transporter 1 (OCT1) variants and severe intolerance to metformin in people with Type 2 diabetes. The aim of this study was to explore the association of OCT1 reduced-function polymorphisms with common metformin-induced gastrointestinal side effects in Type 2 diabetes.

Methods

This prospective observational cohort study included 92 patients with newl

SUBMITTER: Dujic T 

PROVIDER: S-EPMC5064645 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature